Enrofloxacin is a broad-spectrum bactericide with special effect on mycoplasma. It has bactericidal effect on Escherichia coli, Klebsiella, Salmonella, Proteus, Pseudomonas aeruginosa, Haemophilus, Pasteurella multocida, Pasteurella haemolyticus, Staphylococcus aureus and Streptococcus.
Enrofloxacin can be used as an animal drug. It has a long half-life and good tissue distribution in animals. It is a broad-acting bacteriostatic agent. It has bacteriostatic effect on Gram-positive bacteria, negative bacteria and mycoplasma. It has been used to control Vibrio and colibacillosis in cultured fish.
Enrofloxacin is a synthetic third-generation quinolone antibiotic, also known as ethyl ciprofloxacin. It was approved by FDA on October 4, 1996 and is a special quinolone antibiotic for livestock, poultry and aquatic products. It can bind to bacterial DNA cyclotylase subunit A, thus inhibiting the cleavage and ligation of enzymes, preventing the replication of bacterial DNA and showing antimicrobial effect. Enrofloxacin has broad-spectrum antimicrobial activity and strong penetration. Enrofloxacin has strong killing effect on Gram-negative bacteria, good antimicrobial effect on Gram-positive bacteria, good oral absorption, high and stable blood concentration, and can be widely distributed in tissues. Its metabolite is ciprofloxacin, which still has strong antimicrobial effect. 。 Almost all pathogenic bacteria of aquatic animals have strong antimicrobial activity. It is effective for severe infections caused by drug-resistant pathogens and has no cross-resistance with other antibiotics.